US FDA Requests Additional Data on Takeda’s Alogliptin

Takeda Pharmaceuticals have suffered a key setback after US regulators rejected their type 2 diabetes therapy, alogliptin, and the fixed-dose combination of the medicine with Takeda’s Actos. Actos lost patent protection in 2011, and generic versions of the drug are anticipated to hit the marketplace later this year. The business received a second complete response

Continue Reading

Final NICE Approval for Eli Lilly’s Bydureon

The UK’s National Institute for Health and Clinical Excellence (NICE) announced yesterday that they had confirmed in final guidance a endorsement of the use of Eli Lilly’s Bydureon (prolonged-release exenatide) in triple-therapy regimens as a treatment option for people with type 2 diabetes. The director of NICE’s centre for health technology evaluation, Professor Carole Longson,

Continue Reading

Lantus Does Not Increase Cancer Risk, Claims Sanofi

Sanofi yesterday presented new data which they say supports the safety profile of their blockbuster drug, Lantus, hours after dismissing claims from a study that using the diabetes treatment more than doubled the risk of developing cancer. The French giant unveiled new meta-analysis data at the World Diabetes Congress in Dubai, which they say adds

Continue Reading

Pronova Announce Plans To Expand Into Consumer Healthcare

Norway’s Pronova Biopharma, best-known for their fish oil heart drug, Lovaza, from their partnership with GlaxoSmithKline, is to expand into the dietary supplement area of the consumer healthcare market. The Lysaker-based group, who research, develop and manufacture lipid therapies derived from nature, said that the move will build on their position as “the world’s largest

Continue Reading

NICE Draft OK for Eli Lilly Diabetes Drug

The UK’s National Institute for Health and Clinical Excellence (NICE) have issued an initial recommendation of approval for the use of Eli Lilly’s Bydureon (exenatide prolonged-release suspension for injection) in triple-therapy options for people with type 2 diabetes, when control of blood glucose remains or becomes inadequate. NICE commented that Bydureon improves glycaemic control in

Continue Reading

Diabetes is pharma’s fastest-growing market

Diabetes is the pharmaceutical industry’s fastest-growing market, and the costs of preventing and treating the condition worldwide are forecast to rise from $376 billion in 2010 to $490 billion by 2030, according to new research.  285 million people, or 6.4% of the world’s adult population, are currently estimated to be living with diabetes, and this

Continue Reading